Jaguar Health Subsidiary Signs New Manufacturing Agreement
Jaguar Health's wholly-owned subsidiary, Napo Pharmaceuticals, Inc., entered into a new manufacturing and supply agreement with Alivus Life Sciences Limited. This agreement, signed on July 9, 2026, ensures the continued supply of crofelemer, the active pharmaceutical ingredient for Mytesi®, following the expiration of the previous agreement on March 31, 2026. The new contract extends until March 31, 2029, includes minimum purchase commitments, and outlines various termination provisions.
Key Highlights
- Napo Pharmaceuticals, a Jaguar Health subsidiary, signed a new manufacturing agreement with Alivus Life Sciences on July 9, 2026.
- The agreement ensures continued supply of crofelemer for Mytesi® and other crofelemer-based products.
- The new agreement is effective until March 31, 2029, with options for successive renewal terms of at least two years.
- Napo commits to purchasing minimum quantities of crofelemer from Alivus.
- Either party can terminate the agreement with 12 months' prior written notice or 90 days for an uncured material breach.
- Rights and obligations under the agreement may be assigned to Woodward Specialty LLC upon an Insolvency Event.
Price Impact
More from JAGX
Jaguar Health Completes Series O Preferred Stock Conversion; 4.86M Common Shares Outstanding
Jaguar Health Converts Series O Preferred Stock to Common
Jaguar Health Explores Strategic Alternatives for Rare Disease Program